Thesis (DHlthSc) -- Bond University, 2005. / "A thesis submitted to Bond University in fulfillment of the requirements for the degree of Doctor of Health Sciences"-- t.p. Bibliography: pages 379-442. Also available via the World Wide Web.

Thesis (doctoral)--Lund University, 1995. / Added t.p. with thesis statement inserted.

Thesis (doctoral)--Lund University, 1995. / Added t.p. with thesis statement inserted.

Thesis (M.Phil.) - University of Queensland, 2005. / Includes bibliography.

Huai-Hua-Jin-Yin-Jiu, a traditional Chinese medicine (TCM) formula (SL) comprising Sophorae Flos and Lonicerae Japonicae Flos, was used for treating melanoma in ancient China. Our group has previously shown that an ethanolic extract of SL (SLE) possesses anti-melanoma effects, and that inhibiting STAT3 signaling contributes to the action mechanisms. STAT3 activation promotes the formation of an immunosuppressive microenvironment of melanoma. Regulation of the miR-let- 7/CCR7 pathway is a strategy for treating metastatic melanoma. Chrysoeriol is a flavonoid identified in SLE. The compound has anti-tumor properties, but there is no report about its effects on melanoma. The first aim of this study is to determine whether SLE inhibits melanoma progression by reprogramming tumor microenvironment; the second aim is to explore the involvement of miR-let-7a/f- CCR7 signaling in the anti-metastatic effects of SLE; and the third aim is to elucidate the anti-melanoma mode and mechanisms of action of chrysoeriol. Results showed that SLE suppresses melanoma growth and angiogenesis in mice. SLE inhibits STAT3 signaling, and alters immune cell compositions and molecules involved in STAT3 signaling in melanoma tissues. Cell co-culture experiments showed that SLE inhibits STAT3 signaling in melanoma cells and splenic lymphocytes. Over-activation of STAT3 in melanoma cells diminishes SLE's effects in altering compositions of immune cells and STAT3 signaling molecules in the co- culture system. Small RNA sequencing showed that SLE upregulates miR-let-7a/f levels in B16F10 melanomas. RT-qPCR analyses confirms these results. SLE elevates miR-let- 7a/f levels, and inhibits CCR7 (a target gene of miR-let-7a/f) signaling in melanoma cells. In a lung metastasis mouse model, SLE inhibits melanoma metastasis, elevates miR-let-7a/f levels, and suppresses CCR7 signaling. Knockdown of miR-let-7a/f diminishes the effects of SLE on CCR7 signaling and melanoma cell invasion; and overexpression of CCR7 lessens the effects of SLE on melanoma cell invasion. Chrysoeriol shows in vitro and in vivo anti-melanoma effects. Molecular dynamics and microscale thermophoresis assays demonstrate that chrysoeriol directly binds to Src. Chrysoeriol suppresses the Src/STAT3 pathway in melanoma cells and tissues. Chrysoeriol's anti-proliferative effects are diminished by STAT3 over- activation in melanoma cells. Chrysoeriol also has inhibitory effects in vemurafenib- resistant melanoma cell and animal models. RNA-seq analyses shows that syndecan-3 mRNA level is lower in vemurafenib-resistant cells than in vemurafenib-sensitive cells, and chrysoeriol reverses this vemurafenib resistance-associated downregulation. RT-qPCR and Western blotting analyses confirmed the results. In conclusion, we have demonstrated that reprograming immune microenvironment, partially mediated by inhibiting STAT3 signaling, contributes to the anti-melanoma mechanisms of SLE. Regulation of the miR-let-7a/f-CCR7 pathway is another mechanism underlying the anti-melanoma effects of SLE. Chrysoeriol is identified to be one of the active components responsible for the anti- melanoma effects of SLE. Inhibiting the Src/STAT3 pathway contributes to the anti- melanoma mechanisms of chrysoeriol. Chrysoeriol is able to overcome vemurafenib resistance in melanoma, and upregulation of syndecan-3 is involved in the action mechanisms. This study provides further pharmacological and chemical justifications for the use of the formula SL in treating melanoma, and suggests that SLE and SLE- derived compounds have the potential to be developed as modern alternative and/or complimentary agents for melanoma management

Huai-Hua-Jin-Yin-Jiu, a traditional Chinese medicine (TCM) formula (SL) comprising Sophorae Flos and Lonicerae Japonicae Flos, was used for treating melanoma in ancient China. Our group has previously shown that an ethanolic extract of SL (SLE) possesses anti-melanoma effects, and that inhibiting STAT3 signaling contributes to the action mechanisms. STAT3 activation promotes the formation of an immunosuppressive microenvironment of melanoma. Regulation of the miR-let- 7/CCR7 pathway is a strategy for treating metastatic melanoma. Chrysoeriol is a flavonoid identified in SLE. The compound has anti-tumor properties, but there is no report about its effects on melanoma. The first aim of this study is to determine whether SLE inhibits melanoma progression by reprogramming tumor microenvironment; the second aim is to explore the involvement of miR-let-7a/f- CCR7 signaling in the anti-metastatic effects of SLE; and the third aim is to elucidate the anti-melanoma mode and mechanisms of action of chrysoeriol. Results showed that SLE suppresses melanoma growth and angiogenesis in mice. SLE inhibits STAT3 signaling, and alters immune cell compositions and molecules involved in STAT3 signaling in melanoma tissues. Cell co-culture experiments showed that SLE inhibits STAT3 signaling in melanoma cells and splenic lymphocytes. Over-activation of STAT3 in melanoma cells diminishes SLE's effects in altering compositions of immune cells and STAT3 signaling molecules in the co- culture system. Small RNA sequencing showed that SLE upregulates miR-let-7a/f levels in B16F10 melanomas. RT-qPCR analyses confirms these results. SLE elevates miR-let- 7a/f levels, and inhibits CCR7 (a target gene of miR-let-7a/f) signaling in melanoma cells. In a lung metastasis mouse model, SLE inhibits melanoma metastasis, elevates miR-let-7a/f levels, and suppresses CCR7 signaling. Knockdown of miR-let-7a/f diminishes the effects of SLE on CCR7 signaling and melanoma cell invasion; and overexpression of CCR7 lessens the effects of SLE on melanoma cell invasion. Chrysoeriol shows in vitro and in vivo anti-melanoma effects. Molecular dynamics and microscale thermophoresis assays demonstrate that chrysoeriol directly binds to Src. Chrysoeriol suppresses the Src/STAT3 pathway in melanoma cells and tissues. Chrysoeriol's anti-proliferative effects are diminished by STAT3 over- activation in melanoma cells. Chrysoeriol also has inhibitory effects in vemurafenib- resistant melanoma cell and animal models. RNA-seq analyses shows that syndecan-3 mRNA level is lower in vemurafenib-resistant cells than in vemurafenib-sensitive cells, and chrysoeriol reverses this vemurafenib resistance-associated downregulation. RT-qPCR and Western blotting analyses confirmed the results. In conclusion, we have demonstrated that reprograming immune microenvironment, partially mediated by inhibiting STAT3 signaling, contributes to the anti-melanoma mechanisms of SLE. Regulation of the miR-let-7a/f-CCR7 pathway is another mechanism underlying the anti-melanoma effects of SLE. Chrysoeriol is identified to be one of the active components responsible for the anti- melanoma effects of SLE. Inhibiting the Src/STAT3 pathway contributes to the anti- melanoma mechanisms of chrysoeriol. Chrysoeriol is able to overcome vemurafenib resistance in melanoma, and upregulation of syndecan-3 is involved in the action mechanisms. This study provides further pharmacological and chemical justifications for the use of the formula SL in treating melanoma, and suggests that SLE and SLE- derived compounds have the potential to be developed as modern alternative and/or complimentary agents for melanoma management

Thesis (M.S.)--California Polytechnic State University, 2009. / Mode of access: Internet. Title from PDF title page; viewed on Jan. 7, 2010. Major professor: Dr. Lily Laiho. "Presented to the faculty of California Polytechnic State University, San Luis Obispo." "In partial fulfillment of the requirements for the degree [of] Master of Science in Biomedical Engineering." "December, 2009." Includes bibliographical references (p. 113-115).

Diss. (sammanfattning) Stockholm : Karolinska institutet, 2002. / Härtill 5 uppsatser.

Thesis (Ph.D.)--University of Alberta, 2010. / A thesis submitted to the Faculty of Graduate Studies and Research in partial fulfillment of the requirements for the degree of Doctor of Philosophy, Medical Sciences - Medical Genetics. Title from pdf file main screen (viewed on March 19, 2010). Includes bibliographical references.

Diss. (sammanfattning) Stockholm : Karolinska institutet, 2005. / Härtill 4 uppsatser.